Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

Cellular Oncology

Volumn 36, Issue 4, 2013, Pages 277-288

  Peled, Nir ^a,b,c   Wynes, Murry W ^a   Ikeda, Norihiko ^d   Ohira, Tatsuo ^d   Yoshida, Koichi ^d   Qian, Jin ^a   Ilouze, Maya ^b,c   Brenner, Ronen ^b,c   Kato, Yasufumi ^a   Mascaux, Celine ^a   Hirsch, Fred R ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarkers; EGFR; IGF 1R; NSCLC; Therapy resistance

Indexed keywords

GEFITINIB; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CANCER TISSUE; CELL ASSAY; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; UPREGULATION;

EID: 84881622722     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0133-9     Document Type: Article

References (37)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010. CA Cancer J Clin 60, 277-300 (2010)
2. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947-957 (2009)
3. Y. Kato, N. Peled, M.W. Wynes, K. Yoshida, M. Pardo, C. Mascaux, T. Ohira, M. Tsuboi, J. Matsubayashi, T. Nagao, N. Ikeda, F.R. Hirsch, Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5, 1551-1558 (2010)
4. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr., W.A. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J.R. Pereira, T. Ciuleanu, J. von Pawel, C. Watkins, A. Flannery, G. Ellison, E. Donald, L. Knight, D. Parums, N. Botwood, B. Holloway, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24, 5034-5042 (2006)
5. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita, T. Nukiwa, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388 (2010)
6. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J.L. Gonzalez-Larriba, L. Paz-Ares, I. Bover, R. Garcia-Campelo, M.A. Moreno, S. Catot, C. Rolfo, N. Reguart, R. Palmero, J.M. Sanchez, R. Bastus, C. Mayo, J. Bertran-Alamillo, M.A. Molina, J.J. Sanchez, M. Taron, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-967 (2009)
7. K. Tamura, I. Okamoto, T. Kashii, S. Negoro, T. Hirashima, S. Kudoh, Y. Ichinose, N. Ebi, K. Shibata, T. Nishimura, N. Katakami, T. Sawa, E. Shimizu, J. Fukuoka, T. Satoh, M. Fukuoka, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98, 907-914 (2008)
8. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, B. Halmos, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792 (2005)
9. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS medicine 2, e73 (2005)
10. J.A. Engelman, P.A. Janne, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14, 2895-2899 (2008)
11. P.C. Ma, R. Jagadeeswaran, S. Jagadeesh, M.S. Tretiakova, V. Nallasura, E.A. Fox, M. Hansen, E. Schaefer, K. Naoki, A. Lader, W. Richards, D. Sugarbaker, A.N. Husain, J.G. Christensen, R. Salgia, Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65, 1479-1488 (2005)
12. G. Maulik, T. Kijima, P.C. Ma, S.K. Ghosh, J. Lin, G.I. Shapiro, E. Schaefer, E. Tibaldi, B.E. Johnson, R. Salgia, Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8, 620-627 (2002)
13. F. Cappuzzo, P.A. Janne, M. Skokan, G. Finocchiaro, E. Rossi, C. Ligorio, P.A. Zucali, L. Terracciano, L. Toschi, M. Roncalli, A. Destro, M. Incarbone, M. Alloisio, A. Santoro, M. Varella-Garcia, MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20, 298-304 (2009)
14. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, P.A. Janne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007)
15. M. Xie, L. Zhang, C.S. He, F. Xu, J.L. Liu, Z.H. Hu, L.P. Zhao, Y. Tian, Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 113, 1501-1513 (2012)
16. A. Chakravarti, J.S. Loeffler, N.J. Dyson, Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62, 200-207 (2002)
17. Y. Gong, E. Yao, R. Shen, A. Goel, M. Arcila, J. Teruya-Feldstein, M.F. Zakowski, S. Frankel, M. Peifer, R.K. Thomas, M. Ladanyi, W. Pao, High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4, e7273 (2009)
18. A. Hurbin, L. Dubrez, J.L. Coll, M.C. Favrot, Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 277, 49127-49133 (2002)
19. A. Gualberto, M. Pollak, Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28, 3009-3021 (2009)
20. F. Morgillo, J.K. Woo, E.S. Kim, W.K. Hong, H.Y. Lee, Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66, 10100-10111 (2006)
21. V. Ludovini, G. Bellezza, L. Pistola, F. Bianconi, L. Di Carlo, A. Sidoni, A. Semeraro, R. Del Sordo, F.R. Tofanetti, M.G. Mameli, G. Daddi, A. Cavaliere, M. Tonato, L. Crino, High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20, 842-849 (2009)
22. R. Dziadziuszko, D.T. Merrick, S.E. Witta, A.D. Mendoza, B. Szostakiewicz, A. Szymanowska, W. Rzyman, K. Dziadziuszko, J. Jassem, P.A. Bunn Jr., M. Varella-Garcia, F.R. Hirsch, Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28, 2174-2180 (2010)
23. M. Guix, A.C. Faber, S.E. Wang, M.G. Olivares, Y. Song, S. Qu, C. Rinehart, B. Seidel, D. Yee, C.L. Arteaga, J.A. Engelman, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118, 2609-2619 (2008)
24. C.Q. Zhu, G. da Cunha Santos, K. Ding, A. Sakurada, J.C. Cutz, N. Liu, T. Zhang, P. Marrano, M. Whitehead, J.A. Squire, S. Kamel-Reid, L. Seymour, F.A. Shepherd, M.S. Tsao, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26, 4268-4275 (2008)
25. V.A. Miller, G.J. Riely, M.F. Zakowski, A.R. Li, J.D. Patel, R.T. Heelan, M.G. Kris, A.B. Sandler, D.P. Carbone, A. Tsao, R.S. Herbst, G. Heller, M. Ladanyi, W. Pao, D.H. Johnson, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26, 1472-1478 (2008)
26. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris, H.E. Varmus, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine 2, e17 (2005)
27. N.T. W. Brugger, M. Blasinska-Morawiec, S. Curescu, R. Sakalauskas, G. Manikhas, J. Mazieres, R. Whittom, K. Rohr, F. Cappuzzo, on behalf of the SATURN Investigators, Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. ASCO 2009 (2009)
28. P.A. Zucali, M.G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G.L. Ceresoli, J.A. Rodriguez, I. Garassino, P. Comoglio, M. Roncalli, A. Santoro, G. Giaccone, Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 19, 1605-1612 (2008)
29. C. Mascaux, M.W. Wynes, Y. Kato, C. Tran, B.R. Asuncion, J.M. Zhao, M. Gustavson, J. Ranger-Moore, F. Gaire, J. Matsubayashi, T. Nagao, K. Yoshida, T. Ohira, N. Ikeda, F.R. Hirsch, EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor-a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res 17, 7796-7807 (2011)
30. W.D. Travis, E. Brambilla, H.K. Muller-Hermerlink, C.C. Harris, World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the Lung, Pleura, Thymus and Heart (IARC Press, Lyon, 2004)
31. L. Sobin, M. Gospodarowicz and C. Wittekind, TNM classification of malignant tumors, 7th ed, Wiley-Blackwell, (2009)
32. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228-247 (2009)
33. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, R.S. Herbst, W.L. Ince, P.A. Janne, T. Januario, D.H. Johnson, P. Klein, V.A. Miller, M.A. Ostland, D.A. Ramies, D. Sebisanovic, J.A. Stinson, Y.R. Zhang, S. Seshagiri, K.J. Hillan, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23, 5900-5909 (2005)
34. L. Cao, Y. Yu, I. Darko, D. Currier, L.H. Mayeenuddin, X. Wan, C. Khanna, L.J. Helman, Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68, 8039-8048 (2008)
35. M.G. Myers Jr., J.M. Backer, X.J. Sun, S. Shoelson, P. Hu, J. Schlessinger, M. Yoakim, B. Schaffhausen, M.F. White, IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci USA 89, 10350-10354 (1992)
36. F. Cappuzzo, L. Toschi, G. Tallini, G.L. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, R. Trisolini, L. Crino, P.A. Bunn Jr., A. Santoro, W.A. Franklin, M. Varella-Garcia, F.R. Hirsch, Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17, 1120-1127 (2006)
37. M.J. Fidler, S. Basu, L. Buckingham, K. Walters, S. McCormack, M. Batus, J. IV Coon, P. Bonomi, Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res 32, 1705-1710 (2012)